Effects of weight loss in obese subjects with normal fasting plasma glucose or impaired glucose tolerance on insulin release and insulin resistance according to a minimal model analysis

Metabolism: Clinical and Experimental

Volumn 53, Issue 9, 2004, Pages 1095-1100

  Yoshida, Yuriko ^a   Hashimoto, Naotake ^b,c   Tokuyama, Yoshiharu ^a   Kitagawa, Hiroshi ^a   Takahashi, Kazuo ^a   Yagui, Kazuo ^a   Kanatsuka, Azuma ^d   Bujo, Hideaki ^a   Higurashi, Mayumi ^a   Miyazawa, Saori ^a   Yoshida, Shouji ^b   Saito, Yasushi ^a  

^a CHIBA UNIVERSITY   (Japan)

^b Dept of Diabet and Metab Disease ^*  (Japan)

^c ASAHI GENERAL HOSPITAL   (Japan)

^d Kasori Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; LEPTIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); DIET; DISEASE COURSE; DISEASE MODEL; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; UNIVERSITY HOSPITAL; WEIGHT REDUCTION;

ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 2; EXERCISE THERAPY; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; INSULIN RESISTANCE; LIPIDS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; OBESITY; WEIGHT LOSS;

EID: 4344616069     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2004.04.002     Document Type: Article

References (48)

1. DeFronzo R.A., Bonadonna R.C., Ferrannini E. Pathogenesis of NIDDM A balanced overview. Diabetes Care. 15:1992;318-368
2. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607
3. Kaplan N.M. The deadly quartet Upperbody obesity, glucose intolerance, hypertriglycemia, and hypertension. Arch Intern Med. 149:1989;1514-1520
4. DeFronzo R.A., Ferrannini E. A hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194
5. Fujioka S., Matsuzawa Y., Tokunaga K., et al. Contribution of intraabdominal visceral fat accumulation to the impairment of glucose and lipid metabolism in human obesity. Metabolism. 36:1987;54-59
6. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 346:2002;393-403
7. Pan X.R., Li G.W., Hu Y.H., et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care. 20:1977;537-544
8. Faber O.K., Hagen C., Binder C., et al. Kinetics of human connecting peptide in normal and diabetic subjects. J Clin Invest. 62:1978;197-203
9. Eaton R.P., Allen R.C., Schade D.S., et al. Prehepatic insulin production in men Kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab. 51:1980;520-528
10. Polonsky K.S., Licinio-Paixao J., Given B.D., et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type 1 diabetic patients. J Clin Invest. 77:1986;98-105
11. Ferrannini E., Mari A. How to measure insulin sensitivity. J Hypertens. 16:1998;895-906
12. Bergman R.N., Ider Y.Z., Bowden C.R., et al. Quantitative estimation of insulin sensitivity. Am J Physiol. 236:1979;E667-E677
13. Finegood D.T., Hramiak I.M., Dupre J. A modified protocol for estimation of insulin sensitivity with the minimal model of glucose kinetics in patients with insulin-dependent diabetes. J Clin Endocrinol Metab. 70:1990;1538-1549
14. Saad M.F., Steil G.M., Riad-Gabriel M., et al. Method of insulin administration has no effect on insulin sensitivity estimates from the insulin-modified minimal model protocol. Diabetes. 46:1997;2044-2048
15. Kanatsuka A., Makino H., Sakurada M., et al. First phase insulin response to glucose in nonobese or obese subjects with glucose intolerance Analysis by C-peptide secretion rate. Metabolism. 37:1988;878-884
16. Tokuyama Y., Sakurai K., Yagui K., et al. Pathophysiologic phenotypes of Japanese subjects with varying degrees of glucose tolerance Using the combination of C-peptide secretion rate and minimal model analysis. Metabolism. 50:2001;812-818
17. Macor C., Ruggeri A., Mazzonetto P., et al. Visceral adipose tissue impaires insulin secretion and insulin sensitivity but not energy expenditure in obesity. Metabolism. 46:1997;123-129
18. Pacini G., Bergman. MINMOD A computer program to calculate insulin sensitivity and pancreatic responsivity from the frequently sampled intravenous glucose tolerance test. Comput Methods Programs Biomed. 23:1986;113-122
19. Feskens E.J.M. Nutritional factors and the etiology of non-insulin-dependent diabetes mellitus An epidemiological overview. World Rev Nutr Diet. 69:1992;1-39
20. Zimmer P. Type 2 (non-insulin-dependent) diabetes - An epidemiological overview. Diabetologia. 22:1982;399-411
21. Marshall J.A., Hoag S., Shetterly S., et al. Dietary fat predicts conversion from impaired glucose tolerance to NIDDM. Diabetes Care. 17:1994;50-56
22. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose for prevention of type 2 diabetes mellitus The STOP-NIDDM randomized trial. Lancet. 359:2002;2072-2077
23. Muscelli E., Camatra S., Catalano C., et al. Metabolic and cardiovascular assssment in moderate obesity Effect of weight loss. J Clin Endocrinol Metab. 82:1997;2937-2943
24. Sjostrom C.D., Peltonen M., Wedel H., et al. Differentated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension. 36:2000;20-25
25. Ross R., Dagnone D., Jones P.J.H., et al. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. Ann Intern Med. 133:2000;92-103
26. Greco A.V., Mingrone G., Giancaterini A., et al. Insulin resistance in morbid obesity. Diabetes. 51:2002;144-151
27. Polonsky K.S. Evolution of β-cell dysfunction in impaired glucose tolerance and diabetes. Exp Clin Endocrinol Diabetes. 107:1998;S124-S127
28. Hirose H., Maruyama H., Kido K., et al. Alfa- and beta-cell function in obese Zucker (fa/fa) rats A study with the isolated perfused pancreas. Clin Sci. 86:1994;311-316
29. Milburn J.L. Jr, Hirose H., Lee Y.H., et al. Pancreatic β-cells in obesity Evidence for induction of functional, morphogic and metabolic abnormalities by increased lon-chain fatty acids. J Biol Chem. 270:1995;1295-1299
30. Crespin S.R., Greenough W.B. III, Steinberg D. Stimulation of insulin secretion by infusion of free fatty acids. J Clin Invest. 48:1969;1934-1943
31. Sako Y., Grill V.E. A 48-hour lipid infusion in the rat time-dependently inhibits glucose-induced insulin secretion and B cell oxidation through a process likely couplrd to fatty acid oxidation. Endocrinology. 127:1990;1580-1589
32. Elks M.L. Chronic perfusion of rat islets with palmitate suppress glucose-stimulated insulin release. Endocrinology. 133:1993;208-214
33. Widdup G., Bryson J.M., Pawlak D., et al. In vivo and in vitro suppression by leptin of glucose-stimulated insulin hypersecretion in high glucose-ded rats. Eur J Endocrinol. 143:2000;431-437
34. Tsiotra P.C., Tsigos C., Raptis S.A. TNF alfa and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T 15 pancreatic cells. Int J Obes Relat Metab Disord. 25:2001;1018-1026
35. Ahren B., Havel P.J. Leptin inhibits insulin secretion induced by cellular cAMP in a pancreatic B cell line (INS-1 cells). Am J Physiol. 277:1999;R959-R966
36. Seufert J., Kieffer T.J., Leech C.A., et al. Leptin suppression of insulin secretion and gene expression in human pancreatic islets Implications for the development of adipogenic diabetes mellitus. J Clin Endocrinol Metab. 84:1999;670-676
37. Zhao A.Z., Bornfeldt K.E., Beavo J.A. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest. 102:1998;869-873
38. Khan A., Narangoda S., Ahren B., et al. Long-term leptin treatment of ob/ob mice improves glucose-induced insulin secretion. Int J Obes Relat Metab Disord. 25:2001;816-821
39. Islam M.S., Sjoholm A., Emilsson V. Fetal pancreatic islets express functional leptin receptors and leptin stimulates proliferation of fetal islet cells. Int J Obes Relat Metab Disord. 24:2000;1246-1253
40. Tsiotra P.C., Tsigos C., Raptis S.A. TNF alfa and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int J Obes Relat Metab Disord. 25:2001;1018-1026
41. Cases J.A., Gabriely I., Ma X.H., et al. Physiological increase in plasma leptin markedly inhibits insulin secretion in vivo. Diabetes. 50:2001;348-352
42. Widdup G., Bryson J.M., Pawlak D., et al. In vivo and in vitro suppression by leptin of glucose-stimulated insulin hypersecretion in high glucose-fed rats. Eur J Endocrinol. 143:2000;431-437
43. Lee Y., Hirose H., Ohneda M., et al. β-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats Impairment in adipocyte-β cell relationships. Proc Natl Acad Sci USA. 91:1994;10878-10882
44. Higa M., Zhou Y.-T., Ravazzola M., et al. Troglitazone prevents mitochondrial alterations, β cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA. 96:1999;11513-11518
45. Shimomura I., Funahashi T., Takahashi M., et al. Enhanced expression of PAI-1 in visceral fat Possible contributor to vascular disease in obesity. Nat Med. 2:1996;800-803
46. Samad F., Loskutoff D.J. Tissue distribution and regulation of plasminogen activator inhibitor-1 in obese mice. Mol Med. 2:1996;568-582
47. Alessi M.C., Peiretti F., Morange P., et al. Production of plasminogen activator inhibitor 1 by human adipose tissue Possible link between visceral fat accumulation and vascular disease. Diabetes. 46:1997;860-867
48. Mavri A., Stegnar M., Krebs M., et al. Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women. Arterioscler Thromb Vasc Biol. 19:1999;1582-1587